Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan

Abstract

A single dose of AS 03A-adjuvanted, 3.75 μg HA H1N1 2009 pandemic influenza vaccine was highly immunogenic in Japanese adults with a clinically acceptable safety profile, thereby making it a potential candidate for mitigating A/H1N1-associated morbidity and mortality.